Cervical Squamous Cell Carcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Cisplatin, Paclitaxel, Pembrolizumab | |
| FDA (1) HC (1) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab | |
| FDA (1) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Carboplatin, Paclitaxel, Pembrolizumab | |
| FDA (1) HC (1) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab | |
| FDA (1) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Pembrolizumab |